<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4166">
  <stage>Registered</stage>
  <submitdate>24/10/2012</submitdate>
  <approvaldate>24/10/2012</approvaldate>
  <nctid>NCT01724866</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients</studytitle>
    <scientifictitle>Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SPI-GCF-12-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neutropenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - HM10460A (45 µg/kg)
Treatment: drugs - HM10460A (135 µg/kg)
Treatment: drugs - HM10460A (270 µg/kg)
Treatment: drugs - Pegfilgrastim 6mg

Experimental: Single-dose HM10460A (45 µg/kg) - Single-dose HM10460A (45 µg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.

Experimental: Single-dose HM10460A (135 µg/kg) - Single-dose HM10460A (135 µg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.

Experimental: Single-dose HM10460A (270 µg/kg) - Single-dose HM10460A (270 µg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.

Active Comparator: Pegfilgrastim 6 mg - Pegfilgrastim (Neulasta®) is not to be administered between 14 days before or 24 hours after TC chemotherapy. Pegfilgrastim (Neulasta®) will be administered according to the manufacturer's Prescribing Information (6 mg subcutaneously once per chemotherapy cycle).


Treatment: drugs: HM10460A (45 µg/kg)
Single-dose subcutaneous injection

Treatment: drugs: HM10460A (135 µg/kg)
Single-dose subcutaneous injection

Treatment: drugs: HM10460A (270 µg/kg)
Single-dose subcutaneous injection

Treatment: drugs: Pegfilgrastim 6mg
Single-dose subcutaneous injection, per manufacturer's Prescribing Information

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Duration of severe neutropenia (DSN) in Cycle 1 - DSN in Cycle 1, with severe neutropenia defined as ANC &lt; 500 cells/µL (Grade 4 neutropenia, per NCI CTCAE). DSN is defined as the interval from the day of first observation of Grade 4 neutropenia to first ANC recovery to = 2,000 cells/µL (Grade 0). Patients who do not present with Grade 4 neutropenia are censored in this analysis.</outcome>
      <timepoint>Up to 21 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Test Doses of HM10460A - To determine the effect of test doses of HM10460A on the DSN in Cycles 2-4.</outcome>
      <timepoint>Up to 84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Test Doses of HM10460A - To determine the effect of test doses of HM10460A on the absolute neutrophil count (ANC) in Cycles 1-4.</outcome>
      <timepoint>Up to 84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Test Doses of HM10460A - To determine the effect of test doses of HM10460A on the febrile neutropenia (FN) rates by cycle and overall across Cycles 1-4.</outcome>
      <timepoint>Up to 84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Test Doses of HM10460A - To determine the effect of test doses of HM10460A on the number/duration of hospitalizations.</outcome>
      <timepoint>Up to 84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Test Doses of HM10460A - To determine the effect of test doses of HM10460A on the:
 Immunogenicity : The immunogenicity blood sample will be collected to test for antibodies binding to HM10460A and native G-CSF on Day -1 of each cycle (prior to administration of corticosteroids) and at the End of Study Visit.</outcome>
      <timepoint>Up to 84 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed breast cancer who is a candidate for adjuvant or neoadjuvant
             chemotherapy

          -  Candidate for docetaxel and cyclophosphamide chemotherapy

          -  Female or male = 18 years of age

          -  ECOG = 2

          -  ANC = 1.5 x 10^9/L

          -  Platelet count = 100 x 10^9/L

          -  Creatinine = 1.5 x upper limit of normal (ULN)

          -  Total bilirubin = 1.5 mg/dL (= 25.65 µmol/L)

          -  AST/SGOT and/or ALT/SGPT = 2.5 x ULN

          -  Hemoglobin &gt; 9 g/dL

          -  Alkaline phosphatase = 1.5 x ULN</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known sensitivity to E. coli derived products or known sensitivity to any of the
             products to be administered during dosing

          -  Known HIV infection

          -  HBV or HCV diagnosis with detectable viral load or immunological evidence of chronic
             active disease

          -  Active infection or any serious underlying medical condition, which would impair the
             ability of the patient to receive protocol treatment

          -  Prior bone marrow or stem cell transplant

          -  Prolonged exposure to glucocorticosteroids and immunosuppressive agents</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>148</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <hospital>Box Hill Hospital - Melbourne</hospital>
    <hospital>Ashford Cancer Center Research - Kurralta Park</hospital>
    <hospital>Breast Cancer Research Center, WA - Perth</hospital>
    <hospital>Royal Hobart - Tasmania</hospital>
    <hospital>Ballarat Oncology &amp; Haematology - Wendouree</hospital>
    <postcode>3199 - Frankston</postcode>
    <postcode>3065 - Melbourne</postcode>
    <postcode>3128 - Melbourne</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode>7000 - Tasmania</postcode>
    <postcode>3355 - Wendouree</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Mladá Boleslav</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Batumi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyíregyháza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szombathely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Holon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kefar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Poriya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zefat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Grudziadz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kraków</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Racibórz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Suwalki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lomza</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Spectrum Pharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the effect of test doses of HM10460A on the duration
      of severe neutropenia (DSN) during Cycle 1 in patients with breast cancer who are candidates
      for adjuvant or neoadjuvant chemotherapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01724866</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Niederman, MD</name>
      <address>University Cancer Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>